Zherui WU

Dr. Zherui WU

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
PIPhilippe Icard
Philippe Icard
LFLudovic Fournel
Ludovic Fournel
ZWZherui WU
Zherui WU
MAMarco Alifano
Marco Alifano
HLHubert Lincet
Hubert Lincet

1 February 2020 in Cancer Letters
Verified
Journal Article
Closed access
PIPhilippe Icard
Philippe Icard
ZWZherui WU
Zherui WU
LFLudovic Fournel
Ludovic Fournel
ACAntoine Coquerel
Antoine Coquerel
HLHubert Lincet
Hubert Lincet
MAMarco Alifano
Marco Alifano

1 November 2019 in Cancer Letters
Verified
Journal Article
Closed access
Ludovic FournelLudovic Fournel
Ludovic Fournel
ZWZherui WU
Zherui WU
NSNicolas Stadler
Nicolas Stadler
DDDiane Damotte
Diane Damotte
Filippo LococoFilippo Lococo
Filippo Lococo
PFPatricia Forgez
Patricia Forgez

Verified
Journal Article
Open access
PDF file
PIPhilippe Icard
Philippe Icard
ACAntoine Coquerel
Antoine Coquerel
ZWZherui WU
Zherui WU
JGJoseph Gligorov
Joseph Gligorov
David FuksDavid Fuks
David Fuks
LSLuca Simula
Luca Simula
Citrate plays a central role in cancer cells’ metabolism and regulation. Derived from mitochondrial synthesis and/or carboxylation of α-ketoglutarate, it is cleaved by ATP-citrate lyase into acetyl-CoA and oxaloacetate. The rapid turnover of these molecules in proliferative cancer cells maintains a low-level of citrate, precluding its retro-inhibition on glycolytic enzymes. In cancer cells relying on glycolysis, this regulation helps sustain the Warburg effect. In those relying on an oxidative metabolism, fatty acid β-oxidation sustains a high production of citrate, which is still rapidly converted into acetyl-CoA and oxaloacetate, this latter molecule sustaining nucleotide synthesis and gluconeogenesis. Therefore, citrate levels are rarely high in cancer cells. Resistance of cancer cells to targeted therapies, such as tyrosine kinase inhibitors (TKIs), is frequently sustained by aerobic glycolysis and its key oncogenic drivers, such as Ras and its downstream effectors MAPK/ERK and PI3K/Akt. Remarkably, in preclinical cancer models, the administration of high doses of citrate showed various anti-cancer effects, such as the inhibition of glycolysis, the promotion of cytotoxic drugs sensibility and apoptosis, the neutralization of extracellular acidity, and the inhibition of tumors growth and of key signalling pathways (in particular, the IGF-1R/AKT pathway). Therefore, these preclinical results support the testing of the citrate strategy in clinical trials to counteract key oncogenic drivers sustaining cancer development and resistance to anti-cancer therapies.

1 January 2013 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
ZWZherui WU
Zherui WU
DMDaniel Martinez-Fong
Daniel Martinez-Fong
JTJean Trédaniel
Jean Trédaniel
PFPatricia Forgez
Patricia Forgez
Cancer is a worldwide health problem. Personalized treatment represents a future advancement for cancer treatment, in part due to the development of targeted therapeutic drugs. These molecules are expected to be more effective than current treatments and less harmful to normal cells. The discovery and validation of new targets are the foundation and the source of these new therapies. The neurotensinergic system has been shown to enhance cancer progression in various cancers such as pancreatic, prostate, lung, breast, and colon cancer. It also triggers multiple oncogenic signaling pathways, such as the PKC/ERK and AKT pathways. In this review, we discuss the contribution of the neurotensinergic system to cancer progression, as well as the regulation and mechanisms of the system in order to highlight its potential as a therapeutic target, and its prospect for its use as a treatment in certain cancers.

27 September 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
MYMohamad Younes
Mohamad Younes
ZWZherui WU
Zherui WU
SDSandra Dupouy
Sandra Dupouy
ALAudrey Mansuet Lupo
Audrey Mansuet Lupo
NMNajat Mourra
Najat Mourra
PFPatricia Forgez
Patricia Forgez
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib